康众医疗(688607) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was RMB 58,438,952.04, representing a 10.33% increase compared to RMB 52,969,765.80 in the same period last year[3] - The net profit attributable to shareholders was a loss of RMB 3,281,292.00, a decrease of 380.74% from a profit of RMB 1,168,820.49 in the previous year[3] - The basic earnings per share (EPS) was -0.04 RMB, down 479.11% from 0.01 RMB in the same period last year[3] - Total operating revenue for Q1 2025 was CNY 58,438,952.04, an increase of 10.4% compared to CNY 52,969,765.80 in Q1 2024[18] - The net profit for Q1 2025 was a loss of CNY 3,313,077.82, compared to a profit of CNY 1,190,756.45 in Q1 2024, indicating a significant decline in profitability[20] - The operating profit for Q1 2025 was a loss of CNY 1,951,083.79, down from a profit of CNY 2,038,345.06 in Q1 2024[19] Cash Flow - The net cash flow from operating activities was -RMB 34,634,632.56, significantly lower than -RMB 2,277,561.69 in the same period last year[3] - Cash flow from operating activities in Q1 2025 was CNY 69,670,228.34, a decrease from CNY 74,736,111.91 in Q1 2024[22] - The net cash flow from operating activities was -34,634,632.56, a significant decrease compared to -2,277,561.69 from the previous period, indicating a decline in operational efficiency[23] - Cash received from operating activities totaled 72,654,138.33, compared to 82,275,562.79, reflecting a decline in operational cash generation[23] - Cash paid for purchasing goods and services was 61,719,676.18, an increase from 47,638,703.03, indicating rising operational costs[23] Research and Development - Research and development (R&D) expenses totaled RMB 6,792,353.02, a decrease of 34.50% from RMB 10,369,812.18, with R&D expenses accounting for 11.62% of revenue, down 7.95 percentage points[4] - Research and development expenses for Q1 2025 were CNY 6,792,353.02, compared to CNY 10,369,812.18 in Q1 2024, showing a decrease of 34.8%[19] Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 946,078,624.97, a decrease of 2.16% from RMB 966,947,228.28 at the end of the previous year[4] - Total liabilities decreased to CNY 86,718,504.63 from CNY 104,440,158.13, reflecting a reduction of approximately 17%[16] - The company's equity attributable to shareholders was CNY 859,642,422.00, slightly down from CNY 862,540,338.57[16] Shareholder Information - The company reported a total of 12,810,000 shares held by the largest shareholder, Liu Jianqiang, representing 14.54% of total shares[10] - The second-largest shareholder, China-Suzhou Industrial Park Venture Capital Co., Ltd., holds 8,965,203 shares, accounting for 10.17%[10] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending activities[11] Future Outlook and Strategies - There are no significant new strategies or product developments mentioned in the conference call[12] - The company has not disclosed any future outlook or performance guidance in the provided documents[12] Investment Activities - Total cash inflow from investment activities was 517,663,809.70, down from 726,841,799.40, reflecting a reduction in investment returns[23] - The net cash flow from investment activities was 13,674,431.84, a decrease from 42,532,266.14, suggesting a slowdown in investment growth[23] - Cash outflow from financing activities totaled 2,585,236.86, compared to 12,430,996.97 in the previous period, indicating a reduction in financing costs[24] - The net cash flow from financing activities was -2,281,518.81, showing a significant decline from -12,430,996.97, which may impact future funding strategies[24] Inventory and Receivables - The company's accounts receivable slightly decreased to ¥102,898,838.48 from ¥108,079,615.10, indicating a reduction of approximately 4.0%[14] - Inventory increased to ¥99,887,672.71, up from ¥85,966,534.06, reflecting a growth of around 16.2%[14]